|
|
26 June 2020 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Share Purchases
Alliance Pharma plc (AIM: APH), the international healthcare group, was notified on 23 June 2020 that on 23 June 2020 David Cook, Chairman of the Company, purchased 63,879 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 77.7 pence per share, and his spouse, Katharine Cook, also purchased 63,879 Ordinary Shares on the same date at 77.7 pence per share.
Following these transactions, David and Katharine Cook's total beneficial interest in the Company is 234,129 Ordinary Shares, representing approximately 0.04% of the Company's issued share capital.
The notification of dealing forms for Persons Discharging Managerial Responsibility ("PDMR") and Person Closely Associated ("PCA") can be found below. The information contained within this announcement is made in accordance with the requirements of the EU Market Abuse Regulation.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
David Cook |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non-Executive Chairman, PDMR |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Alliance Pharma Plc |
|
|
b) |
Legal Entity Identifier |
213800RYIWZA4Q5WPZ13
|
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 1 pence each
GB0031030819
|
|
|
b) |
Nature of the transaction |
Purchase of shares |
|
|
c) |
Currency |
GBP
|
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
77.7p |
63,879 |
||
|
|
|||
|
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
n/a
|
|
|
f) |
Date of the transaction |
23 June 2020 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Katharine Cook |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PCA with David Cook, Chairman and PDMR |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Alliance Pharma Plc |
|
|
b) |
Legal Entity Identifier |
213800RYIWZA4Q5WPZ13
|
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 1 pence each
GB0031030819
|
|
|
b) |
Nature of the transaction |
Purchase of shares |
|
|
c) |
Currency |
GBP
|
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
77.7p |
63,879 |
||
|
|
|||
|
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
n/a
|
|
|
f) |
Date of the transaction |
23 June 2020 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
For further information:
|
Alliance Pharma plc |
+ 44 (0)1249 466966 |
|
Peter Butterfield, Chief Executive Officer |
|
|
Andrew Franklin, Chief Financial Officer |
|
|
www.alliancepharma.co.uk |
|
|
Buchanan |
+ 44 (0)20 7466 5000 |
|
Mark Court / Hannah Ratcliff |
|
|
|
|
|
Numis Securities Limited |
+ 44 (0)20 7260 1000 |
|
Nominated Adviser: Freddie Barnfield / Huw Jeremy |
|
|
Corporate Broking: James Black |
|
|
Investec Bank plc |
+ 44 (0)20 7597 5970 |
|
Corporate Finance: Daniel Adams / Ed Thomas |
|
|
Corporate Broking: Patrick Robb / Tejas Padalkar |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.
We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
